Dobutamine and milrinone: arrhythmias, hypotension and infusion safety

Two routes to a stronger heartbeat

Dobutamine is a synthetic catecholamine that mainly stimulates beta-1 receptors, increasing contractility and cardiac output with relatively little net change in blood pressure. It has a half-life of about two minutes, so its effects start and fade quickly when the rate changes or the infusion stops.

Milrinone inhibits phosphodiesterase, raising cyclic AMP inside heart muscle and vascular smooth muscle. The heart contracts more strongly while arteries dilate, so blood pressure often falls. Because milrinone acts beyond the beta receptor, its effect is less dependent on beta stimulation, which is one reason prescribers may consider it for patients already taking beta blockers. It is cleared mainly by the kidneys and has a longer half-life than dobutamine.

Adverse effects that drive monitoring

Both drugs increase heart rate and myocardial oxygen demand and can trigger atrial or ventricular arrhythmias, angina or ischaemia. Dobutamine may raise heart rate or blood pressure substantially in some patients and can speed the ventricular response in atrial fibrillation. Milrinone is more likely to cause dose-related hypotension and can cause ventricular tachyarrhythmias.

As output improves, diuresis can lower potassium, which further increases arrhythmia risk. Milrinone may also lower platelets and raise liver enzymes, and it accumulates when kidney function falls. Dobutamine contains sulfite and is contraindicated in hypertrophic obstructive cardiomyopathy, where stronger contraction worsens outflow obstruction.

Haemodynamic targets, infusion safety and escalation

Use continuous ECG monitoring and frequent or arterial blood pressure measurement. Judge effect by perfusion, not just numbers: mental status, skin temperature, capillary refill, urine output and lactate trends. If pulmonary artery catheter values are available, the prescriber's targets for cardiac output or index guide titration within the written order.

Give the drug through a dedicated line on a smart pump, preferably central, and check the site because extravasation can damage tissue. Avoid flushing or bolusing the line carrying an inotrope. Escalate new sustained arrhythmias, chest pain, symptomatic hypotension, a falling urine output or rising lactate, since they may mean the drug is harming more than helping.

Handover and weaning considerations

Handover should include the drug, concentration, current rate, last titration time, the targets in the order and recent trends in heart rate, blood pressure, urine output and lactate. Confirm that the line is labelled and that a backup infusion is prepared, because interruptions can cause a sudden fall in cardiac output.

Weaning is gradual and led by the prescriber. As the rate falls, watch for returning signs of low output, such as cool skin, confusion, falling urine output and rising lactate. With milrinone, effects can persist for hours after stopping, especially when kidney function is reduced, so monitoring continues beyond the end of the infusion.

An original scenario and what to teach

Consider a hypothetical patient with cardiogenic shock on milrinone whose mean arterial pressure drifts below the ordered target and who develops runs of ventricular tachycardia. Choices are to increase the milrinone for more output, flush the line to clear it, or assess, check potassium and magnesium, and notify the prescriber urgently. The last option addresses both instability and a correctable cause. Raising the milrinone rate would likely deepen the hypotension and could worsen the arrhythmia, while flushing an inotrope line can deliver an unintended bolus. Electrolyte replacement and any rate change follow the prescriber's orders and the unit protocol, not a guess at the bedside.

Some patients go home on a continuous inotrope as a bridge to transplant or for symptom relief. Teaching then covers pump alarms, line care and infection signs, daily weights and symptoms to report, such as palpitations, fainting or breathlessness. In exam questions, link home infusion teaching to line safety and arrhythmia recognition.

Sources and further reading

StatPearls: Inotropes and Vasopressors. Mechanisms, arrhythmias, hypokalaemia, extravasation, central access and monitoring for both drugs.

StatPearls: Dobutamine. Beta-1 action, short half-life, contraindications including obstructive cardiomyopathy and sulfite, and atrial fibrillation response.

StatPearls: Milrinone. Renal clearance, hypotension, ventricular arrhythmias, potassium loss and half-life.